company background image

Zealand Pharma CPSE:ZEAL Stock Report

Last Price


Market Cap







04 Oct, 2022


Company Financials +
ZEAL fundamental analysis
Snowflake Score
Future Growth3/6
Past Performance0/6
Financial Health4/6

ZEAL Stock Overview

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark.

Zealand Pharma A/S Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Zealand Pharma
Historical stock prices
Current Share Pricekr.167.00
52 Week Highkr.213.00
52 Week Lowkr.69.55
1 Month Change31.19%
3 Month Change66.00%
1 Year Change-8.64%
3 Year Change5.23%
5 Year Change38.02%
Change since IPO110.06%

Recent News & Updates

Shareholder Returns

ZEALDK BiotechsDK Market

Return vs Industry: ZEAL matched the Danish Biotechs industry which returned -8.9% over the past year.

Return vs Market: ZEAL matched the Danish Market which returned -9.5% over the past year.

Price Volatility

Is ZEAL's price volatile compared to industry and market?
ZEAL volatility
ZEAL Average Weekly Movement11.9%
Biotechs Industry Average Movement8.0%
Market Average Movement5.5%
10% most volatile stocks in DK Market10.5%
10% least volatile stocks in DK Market3.0%

Stable Share Price: ZEAL is more volatile than 90% of Danish stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: ZEAL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Danish stocks.

About the Company

1998237Adam Steensberg

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management.

Zealand Pharma A/S Fundamentals Summary

How do Zealand Pharma's earnings and revenue compare to its market cap?
ZEAL fundamental statistics
Market Capkr.7.73b
Earnings (TTM)-kr.1.09b
Revenue (TTM)kr.293.77m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZEAL income statement (TTM)
Cost of Revenuekr.112.39m
Gross Profitkr.181.38m
Other Expenseskr.1.27b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 10, 2022

Earnings per share (EPS)-23.60
Gross Margin61.74%
Net Profit Margin-371.73%
Debt/Equity Ratio70.9%

How did ZEAL perform over the long term?

See historical performance and comparison